跳至主要内容
临床试验/NCT01235377
NCT01235377已完成4 期

Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study

VA Pharmacy Benefits Management Strategic Healthcare Group10 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年9月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
20
试验地点
10
主要终点
Prescription Rates

研究概览

简要总结

This is a pilot study of a method to compare common, FDA-approved drugs in a clinic. Instead of putting single patients into one of two drug groups, the investigators will assign the doctors who prescribe these drugs for high blood pressure into two groups. One group of doctors has agreed to prescribe mostly ("favor") one drug, chlorthalidone, if that drug would be a good choice for a patient. The other group has agreed to prescribe mostly hydrochlorothiazide. For both groups, they will try to use the doses that were shown to be protective in other trials. If the doctors mostly prescribe the drug they agreed to favor, the investigators will be able to compare outcomes, like heart attacks, in the two groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • VA prescribers of thiazides for hypertension

排除标准

  • at non-participating VA sites

结局指标

主要结局

Prescription Rates

时间窗: nine months

rates of provider prescribing of the Cluster Designated drug

次要结局

  • Factors Associated With Prescribing Patterns(nine months)

研究者

发起方
VA Pharmacy Benefits Management Strategic Healthcare Group
申办方类型
Fed
责任方
Principal Investigator
主要研究者

Madeline McCarren

Biostatistician

VA Pharmacy Benefits Management Strategic Healthcare Group

研究点 (10)

Loading locations...

相似试验